Gold 2021 Pocket Guide - Global Initiative for Chronic ...

1 GOLD Pocket Guide 2021 REFERENCE LIST 1. Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on Chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis 2019; 23(11): 1131-41. 2. Mathers CD, Loncar D. Projections of Global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442. 3. Lange P, Celli B, Agusti A, et al. Lung-Function Trajectories Leading to Chronic obstructive Pulmonary disease . N Engl J Med 2015; 373(2): 111-22. 4. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007; 370(9589): 758-64. 5. Tashkin DP, Altose MD, Bleecker ER, et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group.

2 Am Rev Respir Dis 1992; 145(2 Pt 1): 301-10. 6. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of Chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180(1): 3-10. 7. Raad D, Gaddam S, Schunemann HJ, et al. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. Chest 2011; 139(4): 764-74. 8. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest 2014; 146(4): 924-31. 9. Gunen H, Tarraf H, Nemati A, Al Ghobain M, Al Mutairi S, Aoun Bacah Z. Waterpipe tobacco smoking. Tuberk Toraks 2016; 64(1): 94-6. 10. Tan WC, Lo C, Jong A, et al. Marijuana and Chronic obstructive lung disease : a population-based study. CMAJ 2009; 180(8): 814-20. 11. Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study.

3 Lancet 2007; 370(9589): 751-7. 12. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the Global burden of Chronic obstructive pulmonary disease . Am J Respir Crit Care Med 2010; 182(5): 693-718. 13. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374(9691): 733-43. 14. Ram rez-Venegas A, Vel zquez-Uncal M, Aranda-Ch vez A, et al. Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial. Int J Chron Obstruct Pulmon Dis 2019; 14: 1753-62. 15. Chan KH, Kurmi OP, Bennett DA, et al. Solid Fuel Use and Risks of Respiratory Diseases. A Cohort Study of 280,000 Chinese Never-Smokers. Am J Respir Crit Care Med 2019; 199(3): 352-61. 16. Paulin LM, Diette GB, Blanc PD, et al. Occupational exposures are associated with worse morbidity in patients with Chronic obstructive pulmonary disease .

4 Am J Respir Crit Care Med 2015; 191(5): 557-65. 17. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365(9478): 2225-36. 18. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-608. 19. Ding Z, Wang K, Li J, Tan Q, Tan W, Guo G. Association between glutathione S-transferase gene M1 and T1 polymorphisms and Chronic obstructive pulmonary disease risk: A meta-analysis. Clin Genet 2018. 20. Townend J, Minelli C, Mortimer K, et al. The association between Chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study. Eur Respir J 2017; 49(6). 21. Beran D, Zar HJ, Perrin C, Menezes AM, Burney P, Forum of International Respiratory Societies working group c. Burden of asthma and Chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries.

5 The Lancet Respiratory medicine 2015; 3(2): 159-70. 22. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing Chronic obstructive pulmonary disease : a longitudinal population study. Lancet 2011; 378(9795): 991-6. 23. Kim V, Han MK, Vance GB, et al. The Chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011; 140(3): 626-33. 24. de Marco R, Accordini S, Marcon A, et al. Risk factors for Chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011; 183(7): 891-7. 25. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370(9589): 741-50. 26. Colak Y, Nordestgaard BG, Vestbo J, Lange P, Afzal S. Prognostic significance of Chronic respiratory symptoms in individuals with normal spirometry.

6 Eur Respir J 2019; 54(3). 27. Jackson H, Hubbard R. Detecting Chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ 2003; 327(7416): 653-4. 28. World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva. Licence: CC BY-NC-SA IGO, online document available here: (pen)- disease -interventions-for-primary- health-care [accessed Oct 2020]. 29. WHO meeting participants. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75(5): 397-415. 30. Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J 2017; 50(5). 31. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.

7 N Engl J Med 2003; 348(21): 2059-73. 32. Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 2015; 373(24): 2325-35. 33. Amalakanti S, Pentakota MR. Pulse Oximetry Overestimates Oxygen Saturation in COPD. Respir Care 2016; 61(4): 423-7. 34. Kelly AM, McAlpine R, Kyle E. How accurate are pulse oximeters in patients with acute exacerbations of Chronic obstructive airways disease ? Respir Med 2001; 95(5): 336-40. 35. Durheim MT, Smith PJ, Babyak MA, et al. Six-minute-walk distance and accelerometry predict outcomes in Chronic obstructive pulmonary disease independent of Global Initiative for Chronic obstructive Lung disease 2011 Group. Ann Am Thorac Soc 2015; 12(3): 349-56. 36. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD.

8 Eur Respir J 2004; 23(1): 28-33. 37. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in Chronic obstructive pulmonary disease : role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167(4): 544-9. 38. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in Chronic obstructive pulmonary disease : minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013; 187(4): 382-6. 39. Celli B, Tetzlaff K, Criner G, et al. The 6-Minute-Walk Distance Test as a Chronic obstructive Pulmonary disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med 2016; 194(12): 1483-93. 40. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in Chronic obstructive pulmonary disease .

9 Thorax 1999; 54(3): 213-22. 41. Casanova C, Cote CG, Marin JM, et al. The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J 2007; 29(3): 535-40. 42. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016; 47(2): 429-60. 43. Beekman E, Mesters I, Hendriks EJ, et al. Course length of 30 metres versus 10 metres has a significant influence on six-minute walk distance in patients with COPD: an experimental crossover study. J Physiother 2013; 59(3): 169-76. 44. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140(2): 331-42. 45. Guerra B, Haile SR, Lamprecht B, et al. Large-scale external validation and comparison of prognostic models: an application to Chronic obstructive pulmonary disease .

10 BMC Med 2018; 16(1): 33. 46. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in Chronic obstructive pulmonary disease . N Engl J Med 2004; 350(10): 1005-12. 47. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in Chronic obstructive pulmonary disease : the DOSE Index. Am J Respir Crit Care Med 2009; 180(12): 1189-95. 48. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with Chronic obstructive pulmonary disease : the updated BODE index and the ADO index. Lancet 2009; 374(9691): 704-11. 49. Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic obstructive Pulmonary disease Biomarkers and Their Interpretation. Am J Respir Crit Care Med 2019; 199(10): 1195-204. 50. Celli BR, Anderson JA, Brook R, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.